Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/214303
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Immediate Effects of Dasatinib on the Migration and Redistribution of Naive and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients

AutorColom-Fernández, Beatriz; Kreutzman, Anna; Marcos-Jiménez, Ana; García-Gutiérrez, Valentín; Cuesta-Mateos, Carlos; Portero-Sainz, Itxaso; Pérez-García, Yaiza; Casado, Luis Felipe; Sánchez-Guijo, Fermín M. CSIC ORCID; Martínez-López, Joaquín; Ayala, Rosa; Boqué, Concha; Xicoy, Blanca; Montero, Isabel CSIC ORCID ; Soto, César; Paz, Raquel; Silva, Gabriela; Vega-Piris, Lorena; Steegmann, Juan Luis; Muñoz-Calleja, Cecilia
Palabras claveDasatinib
Lymphocytosis
CCR7
Migration
Chronic myeloid leukemia
Fecha de publicaciónnov-2019
EditorFrontiers Media
CitaciónFrontiers in Pharmacology 10: 1340 (2019)
Resumen[Introduction]: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underlying mechanisms are unknown and SRC family kinases are involved in many cell motility processes, we hypothesized that the movement and migration of lymphocytes is modulated by dasatinib. [Patients, Materials and Methods]: Peripheral blood samples from CML patients treated with second-line dasatinib were collected before and 2 h after the first dasatinib intake, and follow-up samples from the same patients 3 and 6 months after the start of therapy. The migratory capacity and phenotype of lymphocytes and differential blood counts before and after drug intake were compared for all study time-points. [Results]: We report here for the first time that dasatinib intake is associated with inhibition of peripheral blood T-cell migration toward the homeostatic chemokines CCL19 and CCL21, which control the trafficking toward secondary lymphoid organs, mainly the lymph nodes. Accordingly, the proportion of lymphocytes in blood expressing CCR7, the chemokine receptor for both CCL19 and CCL21, decreased after the intake including both naïve CD45RA+ and central memory CD45RO+ T-cells. Similarly, naïve B-cells diminished with dasatinib. Finally, such changes in the migratory patterns did not occur in those patients whose lymphocyte counts remained unchanged after taking the drug. [Discussion]: We, therefore, conclude that lymphocytosis induced by dasatinib reflects a pronounced redistribution of naïve and memory populations of all lymphocyte subsets including CD4+ and CD8+ T-cells and B-cells.
DescripciónCopyright © 2019 Colom-Fernández, Kreutzman, Marcos-Jiménez, García-Gutiérrez, Cuesta-Mateos, Portero-Sainz, Pérez-García, Casado, Sánchez-Guijo, Martínez-López, Ayala, Boqué, Xicoy, Montero, Soto, Paz, Silva, Vega-Piris, Steegmann and Muñoz-Calleja.
Versión del editorhttp://dx.doi.org/10.3389/fphar.2019.01340
URIhttp://hdl.handle.net/10261/214303
DOI10.3389/fphar.2019.01340
E-ISSN1663-9812
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Immediate_Colom_Fernandez_Art2019.pdf2,05 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

7
checked on 13-mar-2024

SCOPUSTM   
Citations

11
checked on 22-mar-2024

WEB OF SCIENCETM
Citations

11
checked on 29-feb-2024

Page view(s)

144
checked on 28-mar-2024

Download(s)

97
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons